Wedbush Reiterates Outperform on Revolution Medicines, Maintains $59 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $59.
August 08, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Revolution Medicines (NASDAQ:RVMD) and maintained a price target of $59.
The reiteration of an Outperform rating and a maintained price target of $59 by a reputable analyst can boost investor confidence in RVMD, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100